7.47 USD
+0.02 (+0.27%)
7.33 USD
-0.14 (-1.87%)
VNDA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. VNDA has a medium profitability rating, but doesn't score so well on its financial health evaluation. VNDA does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
- VNDA had negative earnings in the past year.
- In the past year VNDA has reported a negative cash flow from operations.
- VNDA had positive earnings in 4 of the past 5 years.
- Of the past 5 years VNDA 4 years had a positive operating cash flow.
1.2 Ratios
- With an excellent Return On Assets value of -14.01%, VNDA belongs to the best of the industry, outperforming 80.57% of the companies in the same industry.
- Looking at the Return On Equity, with a value of -18.07%, VNDA belongs to the top of the industry, outperforming 84.34% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.01% | ||
| ROE | -18.07% | ||
| ROIC | N/A |
ROA(3y)-0.5%
ROA(5y)1.69%
ROE(3y)-0.62%
ROE(5y)1.97%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- The Gross Margin of VNDA (94.44%) is better than 94.91% of its industry peers.
- VNDA's Gross Margin has been stable in the last couple of years.
- VNDA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 94.44% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.39%
GM growth 5Y1.12%
2. Health
2.1 Basic Checks
- VNDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, VNDA has more shares outstanding
- VNDA has more shares outstanding than it did 5 years ago.
- The debt/assets ratio for VNDA is higher compared to a year ago.
2.2 Solvency
- Based on the Altman-Z score of 1.56, we must say that VNDA is in the distress zone and has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of 1.56, VNDA is in the better half of the industry, outperforming 65.66% of the companies in the same industry.
- A Debt/Equity ratio of 0.01 indicates that VNDA is not too dependend on debt financing.
- VNDA's Debt to Equity ratio of 0.01 is in line compared to the rest of the industry. VNDA outperforms 46.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.56 |
ROIC/WACCN/A
WACC8.85%
2.3 Liquidity
- VNDA has a Current Ratio of 3.12. This indicates that VNDA is financially healthy and has no problem in meeting its short term obligations.
- With a Current ratio value of 3.12, VNDA is not doing good in the industry: 63.02% of the companies in the same industry are doing better.
- VNDA has a Quick Ratio of 3.10. This indicates that VNDA is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 3.10, VNDA is doing worse than 60.75% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.12 | ||
| Quick Ratio | 3.1 |
3. Growth
3.1 Past
- VNDA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -407.14%.
- The Revenue has grown by 11.12% in the past year. This is quite good.
- Measured over the past years, VNDA shows a decrease in Revenue. The Revenue has been decreasing by -2.64% on average per year.
EPS 1Y (TTM)-407.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-322.22%
Revenue 1Y (TTM)11.12%
Revenue growth 3Y-9.56%
Revenue growth 5Y-2.64%
Sales Q2Q%18.06%
3.2 Future
- VNDA is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -46.02% yearly.
- VNDA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.13% yearly.
EPS Next Y-635.52%
EPS Next 2Y-121.38%
EPS Next 3Y-46.02%
EPS Next 5YN/A
Revenue Next Year9.44%
Revenue Next 2Y16.63%
Revenue Next 3Y20.31%
Revenue Next 5Y1.13%
3.3 Evolution
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
- VNDA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VNDA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A cheap valuation may be justified as VNDA's earnings are expected to decrease with -46.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-121.38%
EPS Next 3Y-46.02%
5. Dividend
5.1 Amount
- No dividends for VNDA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
7.47
+0.02 (+0.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-29 2025-10-29/amc
Earnings (Next)02-11 2026-02-11/amc
Inst Owners78.35%
Inst Owner Change-0.39%
Ins Owners7.03%
Ins Owner Change0.2%
Market Cap441.48M
Revenue(TTM)212.07M
Net Income(TTM)-84.20M
Analysts80
Price Target13.9 (86.08%)
Short Float %8.92%
Short Ratio4.39
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.31%
Min EPS beat(2)-26.44%
Max EPS beat(2)17.82%
EPS beat(4)3
Avg EPS beat(4)8.92%
Min EPS beat(4)-26.44%
Max EPS beat(4)26.47%
EPS beat(8)6
Avg EPS beat(8)-4.56%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-5.83%
Min Revenue beat(2)-6.09%
Max Revenue beat(2)-5.56%
Revenue beat(4)1
Avg Revenue beat(4)-0.79%
Min Revenue beat(4)-6.09%
Max Revenue beat(4)8.7%
Revenue beat(8)3
Avg Revenue beat(8)1.4%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)15.96%
PT rev (3m)7.57%
EPS NQ rev (1m)-37.66%
EPS NQ rev (3m)-239.74%
EPS NY rev (1m)0%
EPS NY rev (3m)-27.72%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-6.6%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-2.98%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.08 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.95 | ||
| P/tB | 1.24 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.42
EYN/A
EPS(NY)-1.57
Fwd EYN/A
FCF(TTM)-1.4
FCFYN/A
OCF(TTM)-1.38
OCFYN/A
SpS3.59
BVpS7.88
TBVpS6.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -14.01% | ||
| ROE | -18.07% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 94.44% | ||
| FCFM | N/A |
ROA(3y)-0.5%
ROA(5y)1.69%
ROE(3y)-0.62%
ROE(5y)1.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.39%
GM growth 5Y1.12%
F-Score3
Asset Turnover0.35
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 13.83% | ||
| Cap/Sales | 0.52% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.12 | ||
| Quick Ratio | 3.1 | ||
| Altman-Z | 1.56 |
F-Score3
WACC8.85%
ROIC/WACCN/A
Cap/Depr(3y)14.89%
Cap/Depr(5y)25.49%
Cap/Sales(3y)0.24%
Cap/Sales(5y)0.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-407.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-322.22%
EPS Next Y-635.52%
EPS Next 2Y-121.38%
EPS Next 3Y-46.02%
EPS Next 5YN/A
Revenue 1Y (TTM)11.12%
Revenue growth 3Y-9.56%
Revenue growth 5Y-2.64%
Sales Q2Q%18.06%
Revenue Next Year9.44%
Revenue Next 2Y16.63%
Revenue Next 3Y20.31%
Revenue Next 5Y1.13%
EBIT growth 1Y-223.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.55%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-425.3%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-415.99%
OCF growth 3YN/A
OCF growth 5YN/A
VANDA PHARMACEUTICALS INC / VNDA FAQ
What is the ChartMill fundamental rating of VANDA PHARMACEUTICALS INC (VNDA) stock?
ChartMill assigns a fundamental rating of 2 / 10 to VNDA.
What is the valuation status of VANDA PHARMACEUTICALS INC (VNDA) stock?
ChartMill assigns a valuation rating of 0 / 10 to VANDA PHARMACEUTICALS INC (VNDA). This can be considered as Overvalued.
What is the profitability of VNDA stock?
VANDA PHARMACEUTICALS INC (VNDA) has a profitability rating of 4 / 10.
Can you provide the financial health for VNDA stock?
The financial health rating of VANDA PHARMACEUTICALS INC (VNDA) is 3 / 10.
What is the expected EPS growth for VANDA PHARMACEUTICALS INC (VNDA) stock?
The Earnings per Share (EPS) of VANDA PHARMACEUTICALS INC (VNDA) is expected to decline by -635.52% in the next year.